Biotech Values

[Bulbaman]

In today’s corporate update, Advaxis CEO O’Connor reported that, as yet, none of the patients in the anal cancer trial have had disease recurrence, with several patients now more than two years post-treatment (in March, Advaxis reported that all 10 of 10 patients in the trial had CRs). He also noted that the historical 3-year recurrence rate for patients similar to those in the Advaxis trial is 45%.
Below is a link to the update webcast. The anal cancer remarks begin at about 12:45.
http://public.viavid.com/player/index.php